{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Thyroid+Gland+Hurthle+Cell+Carcinoma",
    "query": {
      "condition": "Refractory Thyroid Gland Hurthle Cell Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:49:35.988Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03914300",
      "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Differentiated Thyroid Gland Carcinoma",
        "Follicular Variant Thyroid Gland Papillary Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Refractory Differentiated Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Carcinoma",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Follicular Carcinoma",
        "Thyroid Gland Oncocytic Carcinoma",
        "Thyroid Gland Papillary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-02-10",
      "completion_date": "2026-12-17",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 33,
      "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 25 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03914300"
    },
    {
      "nct_id": "NCT02973997",
      "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Columnar Cell Variant Thyroid Gland Papillary Carcinoma",
        "Follicular Variant Thyroid Gland Papillary Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Follicular Carcinoma",
        "Recurrent Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Hurthle Cell Carcinoma",
        "Unresectable Differentiated Thyroid Gland Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2018-02-07",
      "completion_date": "2023-10-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 7,
      "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973997"
    },
    {
      "nct_id": "NCT01811212",
      "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Stage I Thyroid Gland Follicular Carcinoma",
        "Stage I Thyroid Gland Papillary Carcinoma",
        "Stage II Thyroid Gland Follicular Carcinoma",
        "Stage II Thyroid Gland Papillary Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma",
        "Stage III Thyroid Gland Papillary Carcinoma",
        "Stage IVA Thyroid Gland Follicular Carcinoma",
        "Stage IVA Thyroid Gland Papillary Carcinoma",
        "Stage IVB Thyroid Gland Follicular Carcinoma",
        "Stage IVB Thyroid Gland Papillary Carcinoma",
        "Stage IVC Thyroid Gland Follicular Carcinoma",
        "Stage IVC Thyroid Gland Papillary Carcinoma",
        "Tall Cell Variant Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Oncocytic Follicular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-05-08",
      "completion_date": "2017-10-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01811212"
    },
    {
      "nct_id": "NCT00098813",
      "title": "Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Papillary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "romidepsin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-10",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-28",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 1,
      "location_summary": "Commack, New York",
      "locations": [
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098813"
    },
    {
      "nct_id": "NCT00381641",
      "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Carcinoma",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7",
        "Thyroid Gland Oncocytic Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2006-08-29",
      "completion_date": "2024-12-10",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 17,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381641"
    },
    {
      "nct_id": "NCT06959641",
      "title": "XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Differentiated Thyroid Gland Carcinoma",
        "Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma",
        "Locally Advanced Thyroid Gland Follicular Carcinoma",
        "Locally Advanced Thyroid Gland Oncocytic Carcinoma",
        "Locally Advanced Thyroid Gland Papillary Carcinoma",
        "Metastatic Differentiated Thyroid Gland Carcinoma",
        "Metastatic Poorly Differentiated Thyroid Gland Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Oncocytic Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Refractory Differentiated Thyroid Gland Carcinoma",
        "Refractory Poorly Differentiated Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Follicular Carcinoma",
        "Refractory Thyroid Gland Oncocytic Carcinoma",
        "Refractory Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v8",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v8",
        "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v8",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2025-06-06",
      "completion_date": "2030-09-11",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06959641"
    },
    {
      "nct_id": "NCT04544111",
      "title": "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Thyroid Cancer, Follicular",
        "Papillary Thyroid Cancer",
        "Follicular Thyroid Cancer",
        "Hurthle Cell Tumor",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Hurthle Cell Thyroid Neoplasia"
      ],
      "interventions": [
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2020-09-02",
      "completion_date": "2026-09-02",
      "has_results": false,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04544111"
    },
    {
      "nct_id": "NCT01208051",
      "title": "Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Differentiated Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Follicular Carcinoma",
        "Refractory Thyroid Gland Hurthle Cell Carcinoma",
        "Refractory Thyroid Gland Papillary Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cediranib",
          "type": "DRUG"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2010-09-09",
      "completion_date": "2020-02-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-05-22T06:49:35.988Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 24 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01208051"
    }
  ]
}